Apoptosis News and Research RSS Feed - Apoptosis News and Research

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.
HUYA Bioscience International expands HBI-8000 clinical trials for breast cancer

HUYA Bioscience International expands HBI-8000 clinical trials for breast cancer

HUYA Bioscience International (HUYA) today announced expanding clinical trials with its lead cancer drug, HBI-8000, starting with a Phase 1 combination trial in support of a breast cancer program to be conducted in the United States. [More]
Scientists uncover mechanism responsible for development of adrenal gland tumors

Scientists uncover mechanism responsible for development of adrenal gland tumors

Scientists at the Helmholtz Zentrum München have elucidated a mechanism that is responsible for the development of adrenal gland tumors. They discovered that the BMP7 protein plays a key role in this process and that it could be a possible target for future treatments. The results have been published in the journal 'Oncotarget'. [More]
MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics, an immuno-oncology company developing novel therapeutics for the treatment of cancer, today announced that the US Food and Drug Administration has granted Orphan Drug Designation for MTG-201, an advanced biologic therapy targeting Dickkopf-3 gene defects in various cancers, for the treatment of malignant mesothelioma. [More]
PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate APLIDIN (plitidepsin) in Australia and New Zealand. [More]
STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand. [More]
AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

AbbVie, a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis. [More]
In vitro testing provides proof of concept for osteopathic manipulative therapy

In vitro testing provides proof of concept for osteopathic manipulative therapy

In vitro studies of the cellular effects of modeled osteopathic manipulative therapy (OMT) provide proof of concept for the manual techniques practiced by doctors of osteopathic medicine (DOs), according to researchers from the University of Arizona College of Medicine - Phoenix. [More]
Combining chemotherapy and birinapant effective against high-grade serous ovarian cancer

Combining chemotherapy and birinapant effective against high-grade serous ovarian cancer

High-grade serous ovarian cancer often responds well to the chemotherapy drug carboplatin, but why it so frequently comes back after treatment has been a medical mystery. [More]
Researchers uncover new mechanism that p53 protein uses to trigger cell death

Researchers uncover new mechanism that p53 protein uses to trigger cell death

Researchers have identified a new mechanism that the tumor suppressor protein p53 uses to trigger cell death via apoptosis and have shown how the process could be harnessed to kill cancer cells. St. Jude Children's Research Hospital scientists led the study, which appears today in the scientific journal Molecular Cell. [More]
Protecting gastrointestinal system during radiation or chemotherapy allows patients to tolerate cancer treatments

Protecting gastrointestinal system during radiation or chemotherapy allows patients to tolerate cancer treatments

The stem cells in our gut divide so fast that they create a completely new population of epithelial cells every week. But this quick division is also why radiation and chemotherapy wreak havoc on the gastrointestinal systems of cancer patients - such therapies target rapidly dividing cells. [More]
Researchers develop dynamic functional mouse model for lung injury repair

Researchers develop dynamic functional mouse model for lung injury repair

Researchers at Children's Hospital Los Angeles and The Saban Research Institute of CHLA have created a dynamic functional mouse model for lung injury repair, a tool that will help scientists explain the origins of lung disease and provide a system by which new therapies can be identified and tested. [More]
Recipients of GSA poster awards announced at 20th International C. elegans Meeting

Recipients of GSA poster awards announced at 20th International C. elegans Meeting

The Genetics Society of America and the C. elegans research community are pleased to announce the recipients of the GSA poster awards at the 20th International C. elegans Meeting, which took place at the University of California, Los Angeles, June 24-28, 2015. [More]
PharmaMar, TTY Biopharm sign agreement to market and distribute APLIDIN (plitidepsin) in Taiwan

PharmaMar, TTY Biopharm sign agreement to market and distribute APLIDIN (plitidepsin) in Taiwan

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company TTY Biopharm to market and distribute the drug candidate APLIDIN (plitidepsin) in Taiwan. Under the terms of the agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations for regulatory milestones achieved by APLIDIN (plitidepsin). [More]
UC San Diego researchers identify pivotal player in diabetic kidney disease

UC San Diego researchers identify pivotal player in diabetic kidney disease

Tapping the potential of metabolomics, an emerging field focused on the chemical processes of metabolism, researchers at University of California, San Diego School of Medicine have identified a new and pivotal player in diabetic kidney disease. [More]
Dartmouth researchers perform first total syntheses of compounds involved in rapid cell death in leukemia

Dartmouth researchers perform first total syntheses of compounds involved in rapid cell death in leukemia

Dartmouth researchers and their colleagues have carried out the first total syntheses of certain compounds involved in excessive cell death in leukemia. [More]
New research offers potential for early intervention to prevent neurodegenerative diseases

New research offers potential for early intervention to prevent neurodegenerative diseases

New research led by investigators at Beth Israel Deaconess Medical Center provides the first direct evidence linking traumatic brain injury to Alzheimer's disease and chronic traumatic encephalopathy (CTE) -- and offers the potential for early intervention to prevent the development of these debilitating neurodegenerative diseases. [More]
TSRI scientists reveal how mutations in specific autism risk gene alter pattern of early brain development

TSRI scientists reveal how mutations in specific autism risk gene alter pattern of early brain development

As early as 1943, when autism was first described by psychiatrist Leo Kanner, reports were made that some, but not all, children with autism spectrum disorder have relatively enlarged heads. But even today, more than half a century later, the exact cause of this early abnormal growth of the head and brain has remained unclear. [More]
Researchers discover molecule that may favour production of induced pluripotent cells

Researchers discover molecule that may favour production of induced pluripotent cells

Since 2006, research has succeeded in generating, from specialised adult cells, induced pluripotent cells (iPS cells), with huge potential applications, particularly for regenerative medicine. However, the process has still not been completely mastered. Two teams of researchers from Inserm, CNRS, Centre Léon Bérard and Claude Bernard Lyon 1 University have discovered a molecule that may favour the production of these induced stem cells. [More]
Finding could help improve health and function of the kidney in elderly people

Finding could help improve health and function of the kidney in elderly people

As advances in medicine allow individuals to live longer, people are facing unique age-related health challenges. As they age, organs such as the kidneys become more susceptible to injury, and their ability to self-repair is decreased. Researchers from the University of Missouri have found a cellular signal that causes kidney cells to die, making the kidneys prone to injury. [More]
Dental pulp stem cell transplants can contribute to peripheral nerve regeneration

Dental pulp stem cell transplants can contribute to peripheral nerve regeneration

Peripheral nerve injuries often are caused by trauma or surgical complications and can result in considerable disabilities. Regeneration of peripheral nerves can be accomplished effectively using autologous (self-donated) nerve grafts, but that procedure may sacrifice a functional nerve and cause loss of sensation in another part of the patient's body. [More]
Advertisement
Advertisement